News Release - Eli Lilly and Company
WEBINDIANAPOLIS, Aug. 27, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Zepbound ® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to high demand.
Lilly launches lower-price weight loss drug without injector pen - CNN
WEBAug 27, 2024 · The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates...
News Release - Eli Lilly and Company
WEBApr 17, 2024 · Tirzepatide achieved a mean apnea-hypopnea index reduction of up to 63% (about 30 fewer events per hour), meeting all primary and key secondary endpoints in two phase 3 clinical trials. Tirzepatide meaningfully improved sleep apnea symptoms in those with moderate-to-severe OSA and obesity with and …
News Release - Eli Lilly and Company
WEBINDIANAPOLIS, Aug. 1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today positive topline results from the SUMMIT phase 3 clinical trial evaluating the safety and efficacy of tirzepatide injection (5 mg, 10 mg or 15 mg) in adults with heart failure with preserved ejection fraction (HFpEF) and obesity.
Mounjaro and Zepbound Are No Longer in Shortage, F.D.A. Says
WEB7 hours ago · “The entities currently mass-producing and mass-marketing compounded and counterfeit tirzepatide need to stop immediately,” Eli Lilly, the maker of Zepbound and Mounjaro, said in an emailed ...
Eli Lilly & Co: Resolution of Tirzepatide Supply Issue Bolsters Buy ...
WEB23 hours ago · Oct. 3, 2024, 04:25 AM. Deutsche Bank analyst James Shin maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $1,025.00. James Shin has given his Buy ...
Tirzepatide cuts risk of diabetes by 94% in adults with ... - CNN
WEBAug 20, 2024 · A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight...
FDA removes Lilly's Mounjaro and Zepbound from its shortage list
WEB16 hours ago · Eli Lilly’s tirzepatide has been erased from the FDA’s shortage list, freeing Lilly from competing with compounders that are making copycat versions.
Lilly says tirzepatide staves off diabetes in phase 3 trial
WEB3 days ago · Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese...
Eli Lilly's tirzepatide cuts heart failure risks, company says - NBC News
WEBAug 1, 2024 · Eli Lilly’s drug tirzepatide, sold under the names Mounjaro for diabetes and Zepbound for weight loss, improved symptoms in heart failure patients with obesity, the company said Thursday.
- Some results have been removed